NDC 83301-0005-01 - Gabapentin
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 83301-0005
- Requested NDC
- 83301-0005-01
- Package NDCs from labels
- 83301-0005-1, 83301-0005-2, 83301-0005-3, 83301-0005-01
- Manufacturer
- Mullan Pharmaceutical Inc. | CSPC Ouyi Pharmaceutical Co., Ltd
- Effective date
- 2025-08-21
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Gabapentin - Mullan Pharmaceutical Inc. | CSPC Ouyi Pharmaceutical Co., Ltd | Mullan Pharmaceutical Inc. | CSPC Ouyi Pharmaceutical Co., Ltd | 2025-08-21 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 83301-0005-1 | Gabapentin | 100 in 1 BOTTLE, PLASTIC | CAPSULE | 100 | 10 | |
| 83301-0005-2 | Gabapentin | 500 in 1 BOTTLE, PLASTIC | CAPSULE | 500 | 10 | |
| 83301-0005-3 | Gabapentin | 1000 in 1 BOTTLE, PLASTIC | CAPSULE | 1000 | 10 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 83301-0005 | GABAPENTIN CAPSULE [MULLAN PHARMACEUTICAL INC.] | 9 | Current NDC, 3 package rows | 20250411_74474aa4-4859-42d2-92d8-f23f18b34e04.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 83301-0005-1 | EA - Each | 83301-0005 | 8863e540-5809-485e-b28f-833f840df39d | 1 | 2025-07-08 |
| 83301-0005-2 | EA - Each | 83301-0005 | 2fdf46c8-044b-4fb6-8496-b200e820e40c | 1 | 2025-07-08 |
| 83301-0005-3 | EA - Each | 83301-0005 | fbdbf58f-5483-478d-b070-ffd9ed22778b | 1 | 2025-07-08 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Gabapentin | GABAPENTIN | Proficient Rx LP | c7cb37f9-e1df-4e2a-bde5-9bfa0e040d7a | 2022-11-01 | Warnings, Adverse reactions | 310432 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Aphena Pharma Solutions - Tennessee, LLC | 88ac51c4-5fa9-4c35-9c63-f26bcb101d4b | 2022-10-18 | Warnings, Adverse reactions | 310430 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Asclemed USA, Inc. | e89a7ff2-bd82-4fde-b2b7-3b9d0edf6fc8 | 2022-10-12 | Warnings, Adverse reactions | 310430 310431 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Asclemed USA, Inc. | 9d544944-ea95-42e1-8c65-9e442437f0ee | 2022-10-10 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Proficient Rx LP | f651a143-3f88-49c9-b5c4-c9af55aea76a | 2022-10-01 | Warnings, Adverse reactions | 310431 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Proficient Rx LP | 176c5b60-93c2-4574-8b51-c15180912aaa | 2022-08-01 | Warnings, Adverse reactions | 310432 6CW7F3G59X |
| Neurontin | GABAPENTIN | Parke-Davis Div of Pfizer Inc | ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388 | 2022-07-12 | Warnings, Adverse reactions | 310430 310432 310431 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Asclemed USA, Inc. | 14b1840d-a2db-4eec-bc25-029e35b042e4 | 2022-07-09 | Warnings, Adverse reactions | 310432 310431 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Asclemed USA, Inc. | c18d9d06-f796-4eb7-8fd5-1de4ebb95439 | 2022-07-07 | Warnings, Adverse reactions | 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | Aphena Pharma Solutions - Tennessee, LLC | 17988b64-723c-488d-befd-3e4e4cc44bd2 | 2022-05-11 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Proficient Rx LP | ed22b78e-93ff-4cb5-9c9c-2afe9b60dd2e | 2022-05-02 | Warnings, Adverse reactions | 310430 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Proficient Rx LP | 645824d0-eb3d-442b-806d-36a70796cb8e | 2022-05-01 | Warnings, Adverse reactions | 310430 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | Proficient Rx LP | aa3ab216-372a-4a72-bfd1-88a1ffa31ba3 | 2022-05-01 | Warnings, Adverse reactions | 310430 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Proficient Rx LP | b67b7865-df64-429a-9550-5333b9c713ea | 2022-04-01 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Proficient Rx LP | 223a9216-6e07-49b9-8faf-bb4e529a6ae5 | 2022-04-01 | Warnings, Adverse reactions | 310431 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Proficient Rx LP | 2fb2233f-9152-4630-ab39-51a0cda7e5ca | 2022-04-01 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Proficient Rx LP | 52af51ab-6543-466b-848c-13c588c98789 | 2022-04-01 | Warnings, Adverse reactions | 310430 310432 310431 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Proficient Rx LP | 2b76955c-52a4-4026-b286-3da1112fe989 | 2022-04-01 | Warnings, Adverse reactions | 6CW7F3G59X |
| gabapentin | GABAPENTIN | Aphena Pharma Solutions - Tennessee, LLC | 7790d906-af26-4e60-bc6f-e906ec03cc24 | 2022-03-21 | Warnings, Adverse reactions | 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | Aphena Pharma Solutions - Tennessee, LLC | 7f579665-afb7-4227-98c1-2eafee650504 | 2022-02-28 | Warnings, Adverse reactions | 6CW7F3G59X |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.